Importantly, the estimates from this model are sensitive to the expected benefit of initiating therapy for recurrent prostate cancer earlier in the disease course but suggest that even modest (eg, 20%) reductions in the HR for disease progression with delayed vs earlier treatment may support the benefit of PSMA-PET detection. Here, FOLH1 is linked to prostate carcinoma.